Ablation of Intestinal Metaplasia Containing Dysplasia

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
AstraZeneca
Information provided by (Responsible Party):
Covidien, GI Solutions
ClinicalTrials.gov Identifier:
NCT00282672
First received: January 25, 2006
Last updated: January 29, 2014
Last verified: January 2014

January 25, 2006
January 29, 2014
February 2006
April 2014   (final data collection date for primary outcome measure)
  • The % of patients with complete histological clearance of dysplasia within the HGD subgroup (n=63) at 12 months, comparing treatment versus sham control groups. [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • The % of patients with complete histological clearance of IM at 12 months, comparing treatment versus sham control groups (n=127) [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • The % of patients with complete histological clearance of dysplasia within the LGD subgroup (n=64) at 12 months, comparing treatment versus sham control groups. [ Time Frame: 12 Month ] [ Designated as safety issue: No ]
  • 5 year extension: % of all patients enrolled in the extension protocol and available for analysis demonstrating CR-IM at 5 years, and demonstrating CR-dysplasia at 5 years. [ Time Frame: 5 years ] [ Designated as safety issue: No ]
  • • The % of patients with complete histological clearance of IM at 12 months, comparing treatment versus sham control groups (n=120)
  • • The % of patients with complete histological clearance of dysplasia at 12 months, comparing treatment versus sham control groups (n=120)
Complete list of historical versions of study NCT00282672 on ClinicalTrials.gov Archive Site
  • The % of patients with complete histological clearance of dysplasia at 12 months, comparing treatment versus sham control groups (n=127). [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • The % of patients with complete histological clearance of IM at 12 months, comparing treatment versus sham control groups within a specific dysplasia subgroup (LGD [n=64] and HGD [n=63] ) [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Within the HGD subgroup (n=63), the % of patients with complete histological clearance of HGD at 12 months, comparing treatment versus sham control groups. [ Time Frame: 12 Month ] [ Designated as safety issue: No ]
  • Histological clearance of IM (% biopsies) [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Progression of dysplasia (i.e., HGD to adenocarcinoma, or LGD to HGD or adenocarcinoma) [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Regression of dysplasia (i.e., HGD to LGD for HGD group only) [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Subject discomfort at baseline and 0-14 days post-procedure [ Time Frame: 0 and 6 Months for all subjects; 2, 4, 9, and 15 months, if ablated ] [ Designated as safety issue: No ]
  • Quality of Life questionnaire (baseline v. 12 and 24 mos) [ Time Frame: 0, 12, and 24 months ] [ Designated as safety issue: No ]
  • Adverse event incidence [ Time Frame: 12 months for Treatment and Sham Comparison ] [ Designated as safety issue: Yes ]
  • For 5 year extension: Proportion (%) of all patients enrolled in this extension and available for analysis at 5 years demonstrating any adenocarcinoma in any biopsy obtained from the esophageal body since primary RFA (0-5 years) [ Time Frame: 5 years ] [ Designated as safety issue: No ]
  • 5 year extension: Proportion (%) of all patients enrolled in this extension and available for analysis at 5 years demonstrating any adenocarcinoma in any biopsy obtained from the esophageal body after 2 years and inclusive of the 5 year visit [ Time Frame: 5 years ] [ Designated as safety issue: No ]
  • 5 year extension: Proportion (%) of all patients enrolled in this extension protocol and available for analysis demonstrating CR-IM at 3 and 4 years, analyzed separately [ Time Frame: 5 years ] [ Designated as safety issue: No ]
  • 5 year extension:Proportion (%) of all patients enrolled in this extension protocol and available for analysis demonstrating CR-D at 3 and 4 years, analyzed separately [ Time Frame: 5 years ] [ Designated as safety issue: No ]
  • 5 year extension: Proportion (%) of all patients enrolled in this extension protocol and available for analysis demonstrating CR-IM and CR-D (analyzed separately) at 3, 4, and 5 years subgrouped according to entry pathology (LGD, HGD) at randomization [ Time Frame: 5 years ] [ Designated as safety issue: No ]
  • 5 year extension: Proportion of patient-years of trial follow-up spent in CR-IM, calculation commencing after the 2 year interval [ Time Frame: 5 years ] [ Designated as safety issue: No ]
  • 5 year extension: Proportion of all esophageal biopsies collected at 3, 4, 5 years that are free of IM, and separately, free of dysplasia [ Time Frame: 5 years ] [ Designated as safety issue: No ]
  • 5 year extension: Adverse event incidence [ Time Frame: 5 years ] [ Designated as safety issue: Yes ]
  • 5 year extension: All cause mortality of the group from 2 to 5 years. [ Time Frame: 5 years ] [ Designated as safety issue: No ]
  • • Analysis of the primary endpoints for LGD and HGD subgroups:
  • • The % of patients with complete histological clearance of dysplasia at 12 months, comparing treatment versus sham control groups within a specific dysplasia subgroup (n=60 each for LGD and HGD subgroups)
  • • The % of patients with complete histological clearance of IM at 12 months, comparing treatment versus sham control groups within a specific dysplasia subgroup (n=60 each for LGD and HGD subgroups)
  • • Histological clearance of dysplasia in all biopsies for a given subject at follow-up intervals other than 12 months (comparing treatment versus sham control for entire population (n=120) as well as for dysplasia subgroups)
  • • Histological clearance of IM in all biopsies for a given subject at follow-up intervals other than 12 months (comparing treatment versus sham control for entire population (n=120) as well as for dysplasia subgroups)
  • • Histological clearance of dysplasia (% biopsies)
  • • Histological clearance of IM (% biopsies)
  • • Progression of dysplasia (i.e., HGD to adenocarcinoma, or LGD to HGD or adenocarcinoma)
  • • Regression of dysplasia (i.e., HGD to LGD for HGD group only)
  • • Subject discomfort at baseline and 0-14 days post-procedure
  • • Quality of Life questionnaire (baseline v. 12 and 24 mos)
  • • Adverse event incidence
Not Provided
Not Provided
 
Ablation of Intestinal Metaplasia Containing Dysplasia
Ablation of Intestinal Metaplasia Containing Dysplasia (AIM Dysplasia Trial) A Multi-center, Randomized, Sham-Controlled Trial: Protocol Amendment to Extend Follow-up to 5 Years

The purpose of this study is to determine if the intervention of a 510(k)-cleared endoscopically-guided (Halo Ablation systems), ablation system plus anti-secretory therapy is better than anti-secretory therapy alone in clearing Barrett's Esophagus.

Barrett's esophagus or intestinal metaplasia (IM) is a change in the epithelial lining of the esophagus. Barrett's esophagus develops as a result of chronic exposure of the esophagus to refluxed stomach acid and enzymes, as well as bile, resulting in recurrent mucosal injury. Injury is accompanied by inflammation and, ultimately, a cellular change (metaplasia) to a specialized columnar epithelium (Spechler SJ. Barrett's Esophagus. N Engl J Med 2002;346(11):836-842.)

Patients who have a diagnosis of Barrett's esophagus typically undergo surveillance endoscopy every 1-3 years with multiple biopsy specimens obtained to facilitate early detection of progression of IM to dysplasia (more severe precancerous changes) and adenocarcinoma. (Sampliner RE. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastro 2002;97:1888-1895.) Progression of IM to low-grade dysplasia (LGD) indicates that cells exhibit more "cancer-like" architecture, thus warranting an accelerated surveillance endoscopy and biopsy program every 6 months rather than every 1-3 years as indicated for non-dysplastic IM. Progression to high-grade dysplasia (HGD) indicates that the cells are even more "cancer-like", thus warranting an even higher frequency surveillance endoscopy and biopsy program (every 3 months). Many HGD patients may undergo photodynamic therapy (PDT) or surgical esophagectomy, rather than remain in a frequent surveillance program. This more aggressive therapy is warranted because of the high rate of progression of HGD to adenocarcinoma.

Esophageal adenocarcinoma most commonly occurs after an insidious progression from IM to LGD to HGD. Therefore, surveillance is increased upon diagnosis of worsening grades of dysplasia. The incidence of esophageal adenocarcinoma is rapidly increasing as middle-aged and elderly demographic sub-groups expand (Peters JH, Hagen JA, DeMeester SR. Barrett's Esophagus. J Gastrointest Surg 2004;8(1):1-17.) In 2004, the American Cancer Society reported that there were 14,250 new cases of esophageal cancer, and 13,300 deaths attributable to esophageal cancer (www.cancer.org). The U.S. National Cancer Institute Surveillance, Epidemiology and End Results Program reported that the increasing incidence of esophageal adenocarcinoma was greater than for any other cancer in the United States (www.cancer.gov).

Elimination of the diseased epithelium containing IM with dysplasia is an intuitively favorable step for patients with this diagnosis. In other disease states, such as colon polyps or premalignant skin lesions, removal of the premalignant tissue results in a reduction in the risk of ultimately developing cancer. This is a logical conclusion when considering the premalignant lesion of Barrett's esophagus (particularly Barrett's esophagus with dysplasia), as the "tissue at risk" can be completely removed by ablation. This premise has been tested in the Barrett's dysplasia population in photoablative trials using PDT for patients with HGD, where PDT imparted a 50% reduction in risk over controls for the development of adenocarcinoma (Overholt BF, Panjehpour M, Haydek JM. Photodynamic therapy for Barrett's esophagus: follow-up. Gastrointest Endosc 1999;49(1):1-7.) The AIM Dysplasia Trial primary endpoints are removal of all dysplasia and IM, rather than detection of a difference in progression to adenocarcinoma or higher grades of dysplasia.

Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
Barrett Esophagus
  • Device: Ablation System plus anti-secretory medication
    Treatment group subjects undergo up to 4 ablation procedures (circumferential or focal) plus standard anti-secretory drug therapy (proton pump inhibitor, PPI).
    Other Names:
    • HALO 360
    • HALO 90
  • Device: Sham procedure plus anti-secretory medication
    The Sham Control group undergo an upper endoscopy procedure with sizing of the esophageal diameter (a component of the ablation procedure steps, deemed the sham procedure) plus standard anti-secretory drug therapy (Proton pump inhibitor, PPI)
  • Sham Comparator: sham procedure + anti-secretory therapy
    Approximately equal number of subjects with LGD and HGD (Planned 20 in each group). PPI dose: Esomeprazole 40 mg BID.
    Intervention: Device: Sham procedure plus anti-secretory medication
  • Active Comparator: TREATMENT RFA+anti-secretory therapy
    Approximately equal number of subjects with LGD and HGD (Planned 40 in each group).
    Intervention: Device: Ablation System plus anti-secretory medication

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
127
August 2014
April 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:1.Subject is 18-80 years of age, inclusive. 2.Subject has documented diagnosis of IM, maximum endoscopic length of 8 cm (as measured endoscopically from the TGF to the most proximal extent of the IM; i.e. TGF-TIM containing dysplasia as follows:

  1. For LGD:i.LGD documented on biopsy within previous 12 months from enrollment while subject on PPI therapy.

    ii.Histology slides reviewed at central pathology service for trial confirm LGD on first confirmatory central pathology review or, if necessary, confirm LGD on a tie-breaker review by a second pathologist.

  2. For HGD:i.Regular, non-nodular, non-ulcerated mucosa. ii.HGD documented on biopsy within previous 6 months from enrollment. iii.Histology slides reviewed at central pathology service for Trial confirm HGD on first confirmatory review or, if necessary, confirm HGD on a tie-breaker review by a second pathologist.

    iv.Baseline EUS within previous 12 months; 1.Catheter-based EUS excludes suspicious thickened Barrett's areas or, if suspicious areas found, prompts stacked biopsies of thickened area, the results of which do not render subject ineligible for enrollment.

    3.For subjects with EMR history,the documented diagnosis of IM with dysplasia meets criterion #2 from biopsies collected either after the EMR procedure or during the EMR procedure but not from the EMR site.

    4.Subject able to take oral proton pump inhibitor medication. 5.Subject able to discontinue aspirin and/or non-steroidal anti-inflammatory medications 7 days before and after all ablation procedures.

    6.For female subjects of childbearing potential, a negative pregnancy test within 2 weeks of randomization.

    7.Subject eligible for treatment and follow-up endoscopy and biopsy as required by the Protocol.

    8.Subject willing to provide written, informed consent to participate in this clinical study and understands the responsibilities of trial participation.

    Exclusion Criteria:1.The subject is pregnant or planning a pregnancy during the study period.

    2.Esophageal stricture preventing passage of endoscope or catheter. 3.Active esophagitis described as erosions or ulcerations encompassing more than 10% of distal esophagus.

    4.Any history of malignancy of the esophagus. 5.Prior radiation therapy to the esophagus,except head and neck region radiation therapy.

    6.Any previous ablative therapy within the esophagus (PDT, MPEC, APC, laser treatment, other).

    7.History of EMR that meets any of the following criteria:a.EMR performed less than 8 weeks prior to the randomization endoscopy encounter

b.EMR performed in a wide field manner (encompassing more than 90 degrees of any area of the esophagus.

8.Any previous esophageal surgery, including except fundoplication without complications (i.e. no slippage, dysphagia, etc).

9.Evidence of esophageal varices during treatment endoscopy. 10.Report of uncontrolled coagulopathy with international normalized ratio (INR) > 1.3 or platelet count <75,000 platelets per µL 11.Subject has a life-expectancy of less than two years due to an underlying medical condition.

12.Subject has a known history of unresolved drug or alcohol dependency that would limit ability to comprehend or follow instructions related to informed consent, post-treatment instructions, or follow-up guidelines.

13.Subject has an implantable pacing device (examples; AICD, neurostimulator, cardiac pacemaker)and has not received clearance for enrollment in this study by specialist responsible for the pacing device.

14.The subject is currently enrolled in an investigational drug or device trial that clinically interferes with the AIM Dysplasia Trial endpoints.

15.Subject suffers from psychiatric or other illness deemed by the investigator as an inability to comply with protocol.

For the 5 year extension, patient must have:1. Enrolled in the B-204 protocol. 2. Completed 1 year follow-up. 3. Completed 2 year follow-up.

Both
18 Years to 80 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00282672
B-204
Yes
Covidien, GI Solutions
Covidien, GI Solutions
AstraZeneca
Principal Investigator: Nicholas J Shaheen, MD University of North Carolina, Chapel Hill
Covidien, GI Solutions
January 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP